Roger Song
Stock Analyst at Jefferies
(4.22)
# 430
Out of 5,150 analysts
54
Total ratings
51.06%
Success rate
18.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANE Veradermics | Initiates: Buy | $75 | $47.42 | +58.16% | 1 | Mar 2, 2026 | |
| BIOA BioAge Labs | Upgrades: Buy | $9 → $62 | $20.84 | +197.50% | 3 | Feb 18, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $310 → $371 | $263.82 | +40.63% | 2 | Feb 17, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $95 → $118 | $93.96 | +25.59% | 1 | Feb 2, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $13 → $42 | $17.80 | +136.02% | 3 | Jan 22, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $71.99 | +68.08% | 12 | Nov 26, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $34.66 | +29.83% | 1 | Nov 13, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $8.26 | +93.70% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $488.36 | +15.49% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $1.38 | +263.64% | 1 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $17 | $0.96 | +1,672.31% | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $36 | $32.24 | +11.66% | 1 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $54 | $46.00 | +17.39% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $6 | $7.27 | -17.47% | 2 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.26 | +376.19% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.94 | +77.89% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $13.85 | +87.73% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $8.28 | +238.16% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $3.16 | +121.52% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $62.34 | +42.77% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $9.80 | +155.10% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $16.20 | +153.09% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $26.17 | +33.74% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $60.68 | +112.59% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $4.97 | +61.13% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $103.08 | -5.90% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $32.31 | +240.45% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $4.29 | +715.85% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $2.81 | +220.28% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $20.77 | +911.32% | 1 | Sep 2, 2020 |
Veradermics
Mar 2, 2026
Initiates: Buy
Price Target: $75
Current: $47.42
Upside: +58.16%
BioAge Labs
Feb 18, 2026
Upgrades: Buy
Price Target: $9 → $62
Current: $20.84
Upside: +197.50%
Krystal Biotech
Feb 17, 2026
Maintains: Buy
Price Target: $310 → $371
Current: $263.82
Upside: +40.63%
Protagonist Therapeutics
Feb 2, 2026
Maintains: Buy
Price Target: $95 → $118
Current: $93.96
Upside: +25.59%
Corvus Pharmaceuticals
Jan 22, 2026
Maintains: Buy
Price Target: $13 → $42
Current: $17.80
Upside: +136.02%
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $71.99
Upside: +68.08%
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $34.66
Upside: +29.83%
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $8.26
Upside: +93.70%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $488.36
Upside: +15.49%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.38
Upside: +263.64%
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.96
Upside: +1,672.31%
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $32.24
Upside: +11.66%
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $46.00
Upside: +17.39%
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $7.27
Upside: -17.47%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.26
Upside: +376.19%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $3.94
Upside: +77.89%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $13.85
Upside: +87.73%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $8.28
Upside: +238.16%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $3.16
Upside: +121.52%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $62.34
Upside: +42.77%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $9.80
Upside: +155.10%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $16.20
Upside: +153.09%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $26.17
Upside: +33.74%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $60.68
Upside: +112.59%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $4.97
Upside: +61.13%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $103.08
Upside: -5.90%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $32.31
Upside: +240.45%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $4.29
Upside: +715.85%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $2.81
Upside: +220.28%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $20.77
Upside: +911.32%